Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the Convergence of Maximum Likelihood Expectation-maximization Algorithm for Iterative Tomographic Reconstruction and the Role of Spatial Frequency, Location, Pixel Intensity, Contrast, and Noise.

Journal of medical physics·2026
Same author

Truncation Artifact Presenting as Cropped Projections and Wedge Defect in Sinogram During Single-Photon Emission Computed Tomography.

Molecular imaging and radionuclide therapy·2025
Same author

Solar-assisted tri-generation system with LCPV‑CPC and small-scale gas turbine for year-round clean energy in hot-dry climates.

Scientific reports·2025
Same author

Local distortion as a pitfall of iterative MLEM reconstruction in myocardial perfusion imaging - A phantom study.

Journal of applied clinical medical physics·2025
Same author

Predictive optimization using long short-term memory for solar PV and EV integration in relatively cold climate energy systems with a regional case study.

Scientific reports·2025
Same author

Free-space optical spiking neural network.

PloS one·2025
Same journal

Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma: A Potential Diagnostic Pitfall.

Clinical nuclear medicine·2026
Same journal

A Prospective Head-to-Head Comparison of HER2-Targeted and 18F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

Clinical nuclear medicine·2026
Same journal

Epileptogenic Brain Metastasis Early Positive on 18FDG PET/CT Compared to MRI.

Clinical nuclear medicine·2026
Same journal

Dural Manifestation of Langerhans Cell Histiocytosis​: Multimodality Imaging Approach.

Clinical nuclear medicine·2026
Same journal

Malignant Perivascular Epithelioid Cell Tumor (PEComa) of Left Adrenal Gland With Extensive Intravenous Tumor Thrombi: 18F-FDG PET/CT Findings.

Clinical nuclear medicine·2026
Same journal

18F-MFBG Uptake From Multiple Focal "Hot Spots" to Superscan in a Pediatric Patient With High-risk Neuroblastoma.

Clinical nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177 Lu-Prostate-Specific Membrane Antigen Scan.

Mohammad Taghavi1, Reyhane Ahmadi2, Mohsen Qutbi3

  • 1From the Hegmataneh Nuclear Medicine Center.

Clinical Nuclear Medicine
|February 27, 2024
PubMed
Summary
This summary is machine-generated.

This study presents a prostate cancer patient with widespread metastasis who received Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) therapy. The treatment revealed new cutaneous metastatic lesions on the thoracic wall.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.3K

Related Experiment Videos

Last Updated: Jul 2, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.3K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate cancer (PCa) is a leading cause of cancer death globally.
  • Metastatic prostate cancer often spreads to the skeleton and liver.
  • Chemoradiotherapy is a standard treatment for advanced PCa.

Observation:

  • A patient with advanced prostate cancer and widespread skeletal and liver metastases was treated with chemoradiotherapy.
  • The patient subsequently received two doses of 177 Lu-prostate-specific membrane antigen (177Lu-PSMA) therapy.
  • Positron emission tomography (PET) imaging was used to assess treatment response.

Findings:

  • Following 177Lu-PSMA therapy, imaging revealed distinct zones of uptake on the thoracic wall.
  • These uptake zones were indicative of cutaneous metastatic lesions.
  • This suggests a potential pattern of metastatic spread not previously highlighted.

Implications:

  • 177Lu-PSMA therapy may reveal or influence the development of cutaneous metastases in advanced prostate cancer.
  • This finding highlights the importance of comprehensive imaging surveillance during targeted radiopharmaceutical therapy.
  • Further research is warranted to understand the mechanisms and clinical significance of these cutaneous lesions.